Race Oncology is focused on improving the lives of cancer patients around the world by developing a novel approach to both treating the cancer and protecting the heart.

It hopes to address the high unmet need of patients across multiple oncology indications by making use of the unique mechanisms of action of our drug, bisantrene.

Bisantrene, is a small molecule anthracene-based chemotherapeutic that has compelling clinical data demonstrating anti-cancer and cardio-protection effects. Originally developed in the 1970s and 1980’s with the goal of creating a less cardiotoxic, anthracycline-like chemotherapeutic, bisantrene has demonstrated efficacy and a well characterised safety profile having been evaluated in more than 46 clinical trials, and 70 peer reviewed publications, with over 1.8k patients treated.

Leveraging the drug’s rich clinical history, Race is now taking the new bisantrene into two substantial areas of unmet need: metastatic breast cancer (lead indication) and acute myeloid leukaemia (AML).

In 2020, researchers at City of Hope identified that bisantrene was the most potent inhibitor of the Fat mass and obesity-associated protein (FTO). FTO is thought to have a critical role in cancer development and progression. Preclinical studies are being conducted by Race and partners to explore the synergies and impact of bisantrene on FTO regulation.

Led by a highly experienced and passionate leadership team who are supported by a panel of expert global advisors, Race Oncology’s business strategy has evolved to take advantage of recent clinical insights and is outlined in more detail below.